ReviewPersistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis
Introduction
Traumatic brain injury (TBI) is the leading cause of death and disability in individuals less than 45 years of age in industrialized countries (Bruns and Hauser, 2003). Each year an estimated 1.4 million Americans experience a TBI and 80,000 to 90,000 suffer long-term substantial loss of function (Rutland-Brown et al., 2006). Clinical studies have shown that 10–15% of individuals with mild TBI have persistent cognitive and behavioral complaints. Outcomes from moderate TBI are much less favorable with some estimates suggesting that 50% of these individuals endure long-term injury-related disabilities (Kraus et al., 2005). This places an enormous economic burden on the U.S. healthcare system with an estimated cost of $9–10 billion in acute care and rehabilitation annually. This cost is in addition to lost earnings, social services, and the cost to family members who must care for TBI survivors. TBI also represents a global healthcare crisis with an estimated 2% of the world's population suffering from chronic symptoms of brain trauma, equating to more than 120 million individuals (NIH, 1998, Ragnarsson, 2002). For these reasons it has been a long sought goal of TBI researchers to understand the mechanisms of chronic disability after TBI to help develop treatment strategies that may assist patients with cognitive recovery.
However, researching chronic disability following TBI has posed a unique challenge to both clinical and experimental researchers. TBI is a highly variable and extremely complex phenomenon. Following the acute primary injury, which often consists of a focal contusion and more diffuse structural damage, there are a series of subsequent secondary responses, which include, but are not limited to, excitotoxicity, ischemia, oxidative stress, and ongoing structural and chemical alterations (Kochanek, 1993, DeKosky et al., 1998, Park et al., 2008). Traditionally, research in recovery of function after TBI has focused on preventing or manipulating early events in order to prevent chronic dysfunction. Drugs inhibiting apoptosis, blocking glutamate-induced excitotoxicity, or attenuating oxidative stress were designed to reduce cell loss with the premise that neuronal sparing would enhance recovery (Faden et al., 1989, Jennings et al., 2008). Unfortunately, the neuroprotective effects observed in the TBI laboratories have not translated successfully to the clinic (Gualtieri, 1988, Tolias and Bullock, 2004). In contrast, therapeutics used during the rehabilitative phase have shown more promise in addressing long-term disability, although they do not necessarily demonstrate the same level of neuroprotection as drugs designed to inhibit apoptosis or block excitotoxicity (Gualtieri, 1988, Rees et al., 2007).
The failure of translating experimental preventative strategies to clinical efficacy has raised the question about what events in TBI are crucial for long-term outcome. The development of clinically relevant small animal models has greatly assisted the understanding of both acute and chronic TBI-induced alterations in brain chemistry. The two most widely used models of TBI are fluid percussion (FP; Dixon et al., 1987) and controlled cortical impact (CCI; Lighthall, 1988, Lighthall et al., 1989, Dixon et al., 1991, Kline et al., 2001, Kline and Dixon, 2001). Both models produce clinically relevant brain pathology as well as behavioral and cognitive dysfunction in rats and mice (Dixon et al., 1987, Dixon et al., 1991, Hamm et al., 1992, Hamm et al., 1996a, Hamm et al., 1996b, Fox et al., 1998, Fox et al., 1999, Kline et al., 2002, Kline et al., 2007a, Kline et al., 2007b, Wagner et al., 2002, Wagner et al., 2004, Cheng et al., 2007, Cheng et al., 2008, Hoffman et al., 2008a, Hoffman et al., 2008b). Animal studies (Bramlett and Dietrich, 2002, Lifshitz et al., 2007) and human positron emission tomography (PET) imaging (Langfitt et al., 1986, Fontaine et al., 1999, Donnemiller et al., 2000) have shown that in addition to overt damage (e.g., cortical lesions and hippocampal cell loss), there exist areas of chronic dysfunction previously unappreciated, particularly in the striatum and thalamus, which are regions known to have important roles in cognitive, motor, and emotional processing (Vertes, 2006).
The aims of this review are to: (1) highlight the role of dopamine (DA) in cognition and its functional anatomy relevant to TBI; (2) outline clinical research that has demonstrated potential efficacy of DAergic medications in the treatment of TBI; (3) provide an overview of observed changes in DA signaling and anatomy in experimental models, and outline the importance that these alterations have on cognitive and behavioral deficits; and (4) assess future areas of DA systems research in TBI. This review is not meant to be an exhaustive discussion of DA and cognition, but rather is intended to highlight the role(s) DA plays in persistent cognitive dysfunction after TBI, which may provide insight into potential mechanisms and therapeutic targets for chronic cognitive dysfunction. For recent reviews on DA cellular function and DAergic mediated cognition, see Verheij and Cools (2008) and El-Ghundi et al. (2007), respectively.
DA represents a unique signaling system within the central nervous system (CNS) due to its role as both a neurotransmitter and neuromodulator. Furthermore, DA receptors are abundantly expressed in brain areas known to be damaged after TBI, such as the frontal cortex and striatum, which are important for cognitive function (Seeman et al., 1978, Baron et al., 1985, McDonald et al., 2002, Chudasama and Robbins, 2006). The hippocampus, which is also critical for cognitive function does not have a high level of DA receptor expression, but is dependent on DA activity to modulate function (Lemon and Manahan-Vaughan, 2006, O’Carroll et al., 2006, Granado et al., 2008).
Section snippets
Persistent cognitive disability
Cognitive disorders experienced by TBI patients can present immediately after the initial injury or evolve during the subsequent months to years. Regardless of presentation, many patients live with sustained alterations in cognition and behavior for the rest of their lives (Millis et al., 2001). Non-pharmacological options for TBI patients experiencing cognitive and behavioral dysfunction are limited, with cognitive training paradigms often being the only consistent treatment provided. However,
Dopamine at the cellular level: gatekeeper of cognition
In the brain, DAergic neurons arise from the VTA and SN and project to the striatum, cortex, limbic system, and hypothalamus (Graybiel, 1990). DA influences on a number of physiologic functions including hormone secretion, movement control, motivation, emotion, and cognitive processing (Jackson and Westlind-Danielsson, 1994, Floresco and Magyar, 2006).
The unique effects of DA at each of its terminal sites are mediated by membrane receptors belonging to the large seven transmembrane domain (7TM)
Alterations in DAergic systems after TBI
The efficacy of DA receptor agonists suggests that TBI patients benefit from the promotion of central DAergic transmission. This could be a sign that DA release is suppressed after injury, that DA uptake is over active, or some combination of the two. Alternatively, it might be the case that DA activity remains normal after injury, but that basal DA activity is inadequate in the face of the injury-induced disruptions. Given that a few studies have also shown benefits with DA antagonists it must
Dopamine in the clinic: the past and future role of DA agonists and antagonists
In 2006 the Neurotrauma Foundation (NTF) published an excellent review of current clinical recommendations for TBI management in both the acute and rehabilitative phases (Warden et al., 2006). As part of its review the NTF identified three drugs with DAergic effects as current viable options to assist with cognitive recovery. The identified pharmacotherapies were MPD, amantadine hydrochloride (AMH), and bromocriptine. MPD was recommended to enhance attentional function and speed of processing.
Future avenues of DA research in TBI: DA regulation, signaling, and structural plasticity
There remains a significant amount of work in TBI research to explore completely the realities and consequences of DAergic dysfunction after TBI. Are the observed alterations in DAT and TH protein levels a result of injury and ongoing biochemical damage or are they a response to initial changes in DA levels in the cortex and subcortical layers? Furthermore, although no overt cellular damage has been identified within nigrostriatal and mesocortical DAergic pathways, there remains the possibility
Summary
This review has sought to summarize the evidence that supports a DAergic hypothesis of cognitive dysfunction after TBI and provide a context for the use of DA targeted therapies during patient rehabilitation. A concise overview of DA's role in cognitive deficits relevant to TBI, the use of DA therapies in clinical populations to benefit cognitive recovery, and an overview of the alterations observed post-TBI in DA neurotransmission as determined by both clinical and experimental studies allows
Conclusions
Clinical studies coupled with animal research have clearly demonstrated that DA targeted therapies represent an important clinical option in the treatment of memory, learning, and executive function deficiencies that persist following a TBI. However, clinical studies have so far failed to identify the most beneficial dose and time period of administration for DAergic therapy. Furthermore, conclusions from DA enhancement therapeutic trials are further complicated by the nature of TBI itself. TBI
References (417)
- et al.
Functional architecture of basal ganglia circuits: neural substrates of parallel processing
Trends Neurosci.
(1990) - et al.
Partial, graded losses of dopamine terminals in the rat caudate-putamen: an animal model for the study of compensatory adaptation in preclinical parkinsonism
J. Neurosci. Methods
(2001) - et al.
Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain
Brain Res. Mol. Brain Res.
(1997) - et al.
Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury
Pharmacol. Biochem. Behav.
(1990) - et al.
The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease
J. Neurol. Sci.
(1999) - et al.
Positron emission tomography shows that impaired frontal lobe functioning in parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus
Neurosci. Lett.
(2001) - et al.
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder
Neuropsychopharmacology
(2002) - et al.
Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation
Brain Res.
(1996) - et al.
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Trends Neurosci.
(2007) - et al.
Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer
J. Biol. Chem.
(2003)